HIF1A and age-related macular degeneration: Unlike VEGF A, a secretory protein and a primary therapeutic target for the treatment of AMD, HIF-1α has not been considered as a drug target: Indeed, HIF1α in particular and transcription factors in general cannot be targeted directly by antibodies or aptamers or small molecules.